CEL-SCI Corp (CVM) Reports Data Review By IDMC for Its Pivotal Phase 3 Head and Neck Cancer Study
Tweet Send to a Friend
CEL-SCI Corporation (NYSE: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
